Anti-Cerebral Thromboembolism Injection (ACTI), applied intravenously in Cattaneo's animal model of arterial thrombosis, could significantly reduce the weight of thrombus, blood viscosities, plasma TXB2 level and delay the prothrombin time, compared to control group (P < 0.05). From this trial, it was indicated that ACTI's reducing thrombosis action was the result of inhibiting aggregation and releasing of platelets through reducing whole blood viscosities and TXB2 level.
Download full-text PDF |
Source |
---|
Acta Pharmacol Sin
August 2021
Beijing Key Laboratory of Drug Targets Identification and Drug Screening, Centre for Pharmaceutical Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
Hemorrhagic transformation (HT) is a common serious complication of stroke after thrombolysis treatment, which limits the clinical use of tissue plasminogen activator (t-PA). Since early diagnosis and treatment for HT is important to improve the prognosis of stroke patients, it is urgent to discover the potential biomarkers and therapeutic drugs. Recent evidence shows that pinocembrin, a natural flavonoid compound, exerts anti-cerebral ischemia effect and expands the time window of t-PA.
View Article and Find Full Text PDFZhongguo Zhong Xi Yi Jie He Za Zhi
July 1995
Dongzhimen Hospital, Beijing University of TCM.
Anti-Cerebral Thromboembolism Injection (ACTI), applied intravenously in Cattaneo's animal model of arterial thrombosis, could significantly reduce the weight of thrombus, blood viscosities, plasma TXB2 level and delay the prothrombin time, compared to control group (P < 0.05). From this trial, it was indicated that ACTI's reducing thrombosis action was the result of inhibiting aggregation and releasing of platelets through reducing whole blood viscosities and TXB2 level.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!